E-Mycin

Gastroparesis, Erythrasma, Whooping Cough + 60 more
Treatment
68 FDA approvals
20 Active Studies for E-Mycin

What is E-Mycin

ErythromycinThe Generic name of this drug
Treatment SummaryErythromycin is an antibiotic used to treat various bacterial infections. It is a type of macrolide antibiotic, which includes drugs like Azithromycin, Clarithromycin, and Spiramycin. Erythromycin was first discovered in 1952 and can be administered through intravenous, topical, or eye drop preparations.
Erythrocin Stearateis the brand name
image of different drug pills on a surface
E-Mycin Overview & Background
Brand Name
Generic Name
First FDA Approval
How many FDA approvals?
Erythrocin Stearate
Erythromycin
1964
261

Approved as Treatment by the FDA

Erythromycin, also known as Erythrocin Stearate, is approved by the FDA for 68 uses which include Corynebacterium Infections and Urethritis .
Corynebacterium Infections
Urethritis
Erythrasma
Bacterial Infections
Communicable Diseases
Respiratory Tract Infections
Communicable Diseases
Listeriosis
Streptococcus pyogenes
Communicable Diseases
Bacterial Infections
Whooping Cough
Amebiasis
Ureaplasma urethritis
Intestinal amebiasis caused by entamoeba histolytica
Legionella pneumophila
Listeria monocytogenes infection
Corynebacterium minutissimum infection
Recurrent Upper and Lower Respiratory Tract Infections (RTIs)
prophylaxis of Rheumatic fever
penicillins
Upper Respiratory Tract Infection
Streptococcus Pneumoniae Infections
Postoperative Infections
prophylaxis of Postoperative Infections
Whooping Cough
Bordetella Pertussis Infection
Communicable Diseases
uncomplicated endocervical infection
Urethritis
Primary Syphilis
Urinary Tract Infection (UTI)
Corynebacterium Infections
pustular lesions
Used to treat pustular lesions in combination with Avobenzone
Lower Respiratory Tract Infection (LRTI)
Staphylococcus (S.) Aureus Infection
urogenital infections during pregnancy
Staphylococcal Skin Infections
Ureaplasma urealyticum
Conjunctivitis
Acute Otitis Media caused by Haemophilus Influenzae
Used to treat Acute Otitis Media caused by Haemophilus Influenzae in combination with Sulfisoxazole
Pertussis
Pneumonia
Skin and skin structure infections
Diphtheria
Haemophilus Influenzae Infections
Used to treat Haemophilus Influenzae Infections in combination with null
diphtheria antitoxin
Urethritis
Listeria infection
treponema pallidum infection
skin and subcutaneous tissue bacterial infections caused by streptococcus pyogenes
Acne Vulgaris
Used to treat Acne Vulgaris in combination with Tretinoin
Acne Vulgaris
Used to treat predominant skin comedones, papules and pustules in combination with Tretinoin
penicillins
Common Cold
Rheumatic Fever
Staphylococcal Skin Infections
Bronchitis
Pneumonia, Mycoplasma
inflammatory papular lesions
Used to treat inflammatory papular lesions in combination with Avobenzone
Whooping Cough
Chlamydia Trachomatis
patients with intolerance or contraindications to tetracycline use
Syphilis
First episode of rheumatic fever
Rheumatic Fever
Pneumococcal Infections
Sulfonamides

Effectiveness

How E-Mycin Affects PatientsErythromycin is an antibiotic used to treat bacterial infections. It works by blocking the production of proteins in bacteria, which stops them from multiplying and spreading. Erythromycin has been shown to be effective against certain bacteria, but it is important to test for drug-resistance before administering the antibiotic. Combining erythromycin with sulfonamides can be effective against resistant Haemophilus influenzae. It is possible to experience side effects such as pseudomembranous colitis and liver dysfunction when taking erythromycin, so it is important to monitor for these symptoms.
How E-Mycin works in the bodyErythromycin works by preventing bacteria from replicating. It does this by interfering with the protein-making process that bacteria need to reproduce. Erythromycin binds to ribosomal RNA molecules, which are necessary for bacterial protein synthesis. By binding to these molecules, it prevents the assembly of the 50S ribosomal subunit, thus halting bacterial protein synthesis. This results in the effective control of various bacterial infections.

When to interrupt dosage

The proposed dosage of E-Mycin is contingent upon the diagnosed condition, including Chlamydia Trachomatis, penicillins and Syphilis. The dose can differ, depending on the means of administration (e.g. Granule, for suspension or Tablet, film coated - Oral) as specified in the table below.
Condition
Dosage
Administration
Staphylococcus (S.) Aureus Infection
, 333.0 mg, 20.0 mg/mL, 0.02 mg/mg, 250.0 mg, 0.03 mg/mg, 0.005 mg/mg, 500.0 mg, 400.0 mg, 200.0 mg/mL, 400.0 mg/mL, 0.008 mL/mL, 0.0005 mg/mg, 20.0 mg, 600.0 mg, 1000.0 mg, 0.5 %, 4.0 %, 200.0 mg, 2.0 %, 50.0 mg/mL, 5.0 mg/mL, 15.0 mg/mL, 3.1 mg/mg, 100.0 mg/mL, 3.0 %, 125.0 mg/mL, 25.0 mg/mL, 250.0 mg/mL, 40.0 mg/mL, 0.0012 mg/mg, 0.12 mg/mg
, Kit, Solution, Topical, Solution - Topical, Gel, Gel - Topical, Oral, Tablet, film coated, Tablet, film coated - Oral, Capsule, delayed release, Capsule, delayed release - Oral, Tablet, delayed release, Tablet, delayed release - Oral, Ointment, Ophthalmic, Ointment - Ophthalmic, Granule, for suspension - Oral, Tablet, Tablet - Oral, Suspension, Suspension - Oral, Granule, for suspension, Capsule, delayed release pellets, Capsule, delayed release pellets - Oral, Intravenous, Powder, for solution, Powder, for solution - Intravenous, Liquid, Liquid - Oral, Powder, for solution - Oral, Capsule, Capsule - Oral, Powder, Powder - Oral, Lotion, Lotion - Topical, Lotion; Swab, Lotion; Swab - Topical, Kit - Topical, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous, Powder, for suspension, Powder, for suspension - Oral, Capsule, Delayed Release - Oral, Capsule, Delayed Release, Ointment - Topical, Wafer, Wafer - Oral, Capsule, coated pellets, Capsule, coated pellets - Oral, Injection, powder, for solution, Injection, powder, for solution - Intravenous, Swab - Topical, Swab, For suspension, For suspension - Oral, Tablet, coated, Tablet, coated - Oral
Gastroparesis
, 333.0 mg, 20.0 mg/mL, 0.02 mg/mg, 250.0 mg, 0.03 mg/mg, 0.005 mg/mg, 500.0 mg, 400.0 mg, 200.0 mg/mL, 400.0 mg/mL, 0.008 mL/mL, 0.0005 mg/mg, 20.0 mg, 600.0 mg, 1000.0 mg, 0.5 %, 4.0 %, 200.0 mg, 2.0 %, 50.0 mg/mL, 5.0 mg/mL, 15.0 mg/mL, 3.1 mg/mg, 100.0 mg/mL, 3.0 %, 125.0 mg/mL, 25.0 mg/mL, 250.0 mg/mL, 40.0 mg/mL, 0.0012 mg/mg, 0.12 mg/mg
, Kit, Solution, Topical, Solution - Topical, Gel, Gel - Topical, Oral, Tablet, film coated, Tablet, film coated - Oral, Capsule, delayed release, Capsule, delayed release - Oral, Tablet, delayed release, Tablet, delayed release - Oral, Ointment, Ophthalmic, Ointment - Ophthalmic, Granule, for suspension - Oral, Tablet, Tablet - Oral, Suspension, Suspension - Oral, Granule, for suspension, Capsule, delayed release pellets, Capsule, delayed release pellets - Oral, Intravenous, Powder, for solution, Powder, for solution - Intravenous, Liquid, Liquid - Oral, Powder, for solution - Oral, Capsule, Capsule - Oral, Powder, Powder - Oral, Lotion, Lotion - Topical, Lotion; Swab, Lotion; Swab - Topical, Kit - Topical, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous, Powder, for suspension, Powder, for suspension - Oral, Capsule, Delayed Release - Oral, Capsule, Delayed Release, Ointment - Topical, Wafer, Wafer - Oral, Capsule, coated pellets, Capsule, coated pellets - Oral, Injection, powder, for solution, Injection, powder, for solution - Intravenous, Swab - Topical, Swab, For suspension, For suspension - Oral, Tablet, coated, Tablet, coated - Oral
Erythrasma
, 333.0 mg, 20.0 mg/mL, 0.02 mg/mg, 250.0 mg, 0.03 mg/mg, 0.005 mg/mg, 500.0 mg, 400.0 mg, 200.0 mg/mL, 400.0 mg/mL, 0.008 mL/mL, 0.0005 mg/mg, 20.0 mg, 600.0 mg, 1000.0 mg, 0.5 %, 4.0 %, 200.0 mg, 2.0 %, 50.0 mg/mL, 5.0 mg/mL, 15.0 mg/mL, 3.1 mg/mg, 100.0 mg/mL, 3.0 %, 125.0 mg/mL, 25.0 mg/mL, 250.0 mg/mL, 40.0 mg/mL, 0.0012 mg/mg, 0.12 mg/mg
, Kit, Solution, Topical, Solution - Topical, Gel, Gel - Topical, Oral, Tablet, film coated, Tablet, film coated - Oral, Capsule, delayed release, Capsule, delayed release - Oral, Tablet, delayed release, Tablet, delayed release - Oral, Ointment, Ophthalmic, Ointment - Ophthalmic, Granule, for suspension - Oral, Tablet, Tablet - Oral, Suspension, Suspension - Oral, Granule, for suspension, Capsule, delayed release pellets, Capsule, delayed release pellets - Oral, Intravenous, Powder, for solution, Powder, for solution - Intravenous, Liquid, Liquid - Oral, Powder, for solution - Oral, Capsule, Capsule - Oral, Powder, Powder - Oral, Lotion, Lotion - Topical, Lotion; Swab, Lotion; Swab - Topical, Kit - Topical, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous, Powder, for suspension, Powder, for suspension - Oral, Capsule, Delayed Release - Oral, Capsule, Delayed Release, Ointment - Topical, Wafer, Wafer - Oral, Capsule, coated pellets, Capsule, coated pellets - Oral, Injection, powder, for solution, Injection, powder, for solution - Intravenous, Swab - Topical, Swab, For suspension, For suspension - Oral, Tablet, coated, Tablet, coated - Oral
Lymphogranuloma Venereum
, 333.0 mg, 20.0 mg/mL, 0.02 mg/mg, 250.0 mg, 0.03 mg/mg, 0.005 mg/mg, 500.0 mg, 400.0 mg, 200.0 mg/mL, 400.0 mg/mL, 0.008 mL/mL, 0.0005 mg/mg, 20.0 mg, 600.0 mg, 1000.0 mg, 0.5 %, 4.0 %, 200.0 mg, 2.0 %, 50.0 mg/mL, 5.0 mg/mL, 15.0 mg/mL, 3.1 mg/mg, 100.0 mg/mL, 3.0 %, 125.0 mg/mL, 25.0 mg/mL, 250.0 mg/mL, 40.0 mg/mL, 0.0012 mg/mg, 0.12 mg/mg
, Kit, Solution, Topical, Solution - Topical, Gel, Gel - Topical, Oral, Tablet, film coated, Tablet, film coated - Oral, Capsule, delayed release, Capsule, delayed release - Oral, Tablet, delayed release, Tablet, delayed release - Oral, Ointment, Ophthalmic, Ointment - Ophthalmic, Granule, for suspension - Oral, Tablet, Tablet - Oral, Suspension, Suspension - Oral, Granule, for suspension, Capsule, delayed release pellets, Capsule, delayed release pellets - Oral, Intravenous, Powder, for solution, Powder, for solution - Intravenous, Liquid, Liquid - Oral, Powder, for solution - Oral, Capsule, Capsule - Oral, Powder, Powder - Oral, Lotion, Lotion - Topical, Lotion; Swab, Lotion; Swab - Topical, Kit - Topical, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous, Powder, for suspension, Powder, for suspension - Oral, Capsule, Delayed Release - Oral, Capsule, Delayed Release, Ointment - Topical, Wafer, Wafer - Oral, Capsule, coated pellets, Capsule, coated pellets - Oral, Injection, powder, for solution, Injection, powder, for solution - Intravenous, Swab - Topical, Swab, For suspension, For suspension - Oral, Tablet, coated, Tablet, coated - Oral
Syphilis
, 333.0 mg, 20.0 mg/mL, 0.02 mg/mg, 250.0 mg, 0.03 mg/mg, 0.005 mg/mg, 500.0 mg, 400.0 mg, 200.0 mg/mL, 400.0 mg/mL, 0.008 mL/mL, 0.0005 mg/mg, 20.0 mg, 600.0 mg, 1000.0 mg, 0.5 %, 4.0 %, 200.0 mg, 2.0 %, 50.0 mg/mL, 5.0 mg/mL, 15.0 mg/mL, 3.1 mg/mg, 100.0 mg/mL, 3.0 %, 125.0 mg/mL, 25.0 mg/mL, 250.0 mg/mL, 40.0 mg/mL, 0.0012 mg/mg, 0.12 mg/mg
, Kit, Solution, Topical, Solution - Topical, Gel, Gel - Topical, Oral, Tablet, film coated, Tablet, film coated - Oral, Capsule, delayed release, Capsule, delayed release - Oral, Tablet, delayed release, Tablet, delayed release - Oral, Ointment, Ophthalmic, Ointment - Ophthalmic, Granule, for suspension - Oral, Tablet, Tablet - Oral, Suspension, Suspension - Oral, Granule, for suspension, Capsule, delayed release pellets, Capsule, delayed release pellets - Oral, Intravenous, Powder, for solution, Powder, for solution - Intravenous, Liquid, Liquid - Oral, Powder, for solution - Oral, Capsule, Capsule - Oral, Powder, Powder - Oral, Lotion, Lotion - Topical, Lotion; Swab, Lotion; Swab - Topical, Kit - Topical, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous, Powder, for suspension, Powder, for suspension - Oral, Capsule, Delayed Release - Oral, Capsule, Delayed Release, Ointment - Topical, Wafer, Wafer - Oral, Capsule, coated pellets, Capsule, coated pellets - Oral, Injection, powder, for solution, Injection, powder, for solution - Intravenous, Swab - Topical, Swab, For suspension, For suspension - Oral, Tablet, coated, Tablet, coated - Oral
Whooping Cough
, 333.0 mg, 20.0 mg/mL, 0.02 mg/mg, 250.0 mg, 0.03 mg/mg, 0.005 mg/mg, 500.0 mg, 400.0 mg, 200.0 mg/mL, 400.0 mg/mL, 0.008 mL/mL, 0.0005 mg/mg, 20.0 mg, 600.0 mg, 1000.0 mg, 0.5 %, 4.0 %, 200.0 mg, 2.0 %, 50.0 mg/mL, 5.0 mg/mL, 15.0 mg/mL, 3.1 mg/mg, 100.0 mg/mL, 3.0 %, 125.0 mg/mL, 25.0 mg/mL, 250.0 mg/mL, 40.0 mg/mL, 0.0012 mg/mg, 0.12 mg/mg
, Kit, Solution, Topical, Solution - Topical, Gel, Gel - Topical, Oral, Tablet, film coated, Tablet, film coated - Oral, Capsule, delayed release, Capsule, delayed release - Oral, Tablet, delayed release, Tablet, delayed release - Oral, Ointment, Ophthalmic, Ointment - Ophthalmic, Granule, for suspension - Oral, Tablet, Tablet - Oral, Suspension, Suspension - Oral, Granule, for suspension, Capsule, delayed release pellets, Capsule, delayed release pellets - Oral, Intravenous, Powder, for solution, Powder, for solution - Intravenous, Liquid, Liquid - Oral, Powder, for solution - Oral, Capsule, Capsule - Oral, Powder, Powder - Oral, Lotion, Lotion - Topical, Lotion; Swab, Lotion; Swab - Topical, Kit - Topical, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous, Powder, for suspension, Powder, for suspension - Oral, Capsule, Delayed Release - Oral, Capsule, Delayed Release, Ointment - Topical, Wafer, Wafer - Oral, Capsule, coated pellets, Capsule, coated pellets - Oral, Injection, powder, for solution, Injection, powder, for solution - Intravenous, Swab - Topical, Swab, For suspension, For suspension - Oral, Tablet, coated, Tablet, coated - Oral
Chancroid
, 333.0 mg, 20.0 mg/mL, 0.02 mg/mg, 250.0 mg, 0.03 mg/mg, 0.005 mg/mg, 500.0 mg, 400.0 mg, 200.0 mg/mL, 400.0 mg/mL, 0.008 mL/mL, 0.0005 mg/mg, 20.0 mg, 600.0 mg, 1000.0 mg, 0.5 %, 4.0 %, 200.0 mg, 2.0 %, 50.0 mg/mL, 5.0 mg/mL, 15.0 mg/mL, 3.1 mg/mg, 100.0 mg/mL, 3.0 %, 125.0 mg/mL, 25.0 mg/mL, 250.0 mg/mL, 40.0 mg/mL, 0.0012 mg/mg, 0.12 mg/mg
, Kit, Solution, Topical, Solution - Topical, Gel, Gel - Topical, Oral, Tablet, film coated, Tablet, film coated - Oral, Capsule, delayed release, Capsule, delayed release - Oral, Tablet, delayed release, Tablet, delayed release - Oral, Ointment, Ophthalmic, Ointment - Ophthalmic, Granule, for suspension - Oral, Tablet, Tablet - Oral, Suspension, Suspension - Oral, Granule, for suspension, Capsule, delayed release pellets, Capsule, delayed release pellets - Oral, Intravenous, Powder, for solution, Powder, for solution - Intravenous, Liquid, Liquid - Oral, Powder, for solution - Oral, Capsule, Capsule - Oral, Powder, Powder - Oral, Lotion, Lotion - Topical, Lotion; Swab, Lotion; Swab - Topical, Kit - Topical, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous, Powder, for suspension, Powder, for suspension - Oral, Capsule, Delayed Release - Oral, Capsule, Delayed Release, Ointment - Topical, Wafer, Wafer - Oral, Capsule, coated pellets, Capsule, coated pellets - Oral, Injection, powder, for solution, Injection, powder, for solution - Intravenous, Swab - Topical, Swab, For suspension, For suspension - Oral, Tablet, coated, Tablet, coated - Oral
Diphtheria
, 333.0 mg, 20.0 mg/mL, 0.02 mg/mg, 250.0 mg, 0.03 mg/mg, 0.005 mg/mg, 500.0 mg, 400.0 mg, 200.0 mg/mL, 400.0 mg/mL, 0.008 mL/mL, 0.0005 mg/mg, 20.0 mg, 600.0 mg, 1000.0 mg, 0.5 %, 4.0 %, 200.0 mg, 2.0 %, 50.0 mg/mL, 5.0 mg/mL, 15.0 mg/mL, 3.1 mg/mg, 100.0 mg/mL, 3.0 %, 125.0 mg/mL, 25.0 mg/mL, 250.0 mg/mL, 40.0 mg/mL, 0.0012 mg/mg, 0.12 mg/mg
, Kit, Solution, Topical, Solution - Topical, Gel, Gel - Topical, Oral, Tablet, film coated, Tablet, film coated - Oral, Capsule, delayed release, Capsule, delayed release - Oral, Tablet, delayed release, Tablet, delayed release - Oral, Ointment, Ophthalmic, Ointment - Ophthalmic, Granule, for suspension - Oral, Tablet, Tablet - Oral, Suspension, Suspension - Oral, Granule, for suspension, Capsule, delayed release pellets, Capsule, delayed release pellets - Oral, Intravenous, Powder, for solution, Powder, for solution - Intravenous, Liquid, Liquid - Oral, Powder, for solution - Oral, Capsule, Capsule - Oral, Powder, Powder - Oral, Lotion, Lotion - Topical, Lotion; Swab, Lotion; Swab - Topical, Kit - Topical, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous, Powder, for suspension, Powder, for suspension - Oral, Capsule, Delayed Release - Oral, Capsule, Delayed Release, Ointment - Topical, Wafer, Wafer - Oral, Capsule, coated pellets, Capsule, coated pellets - Oral, Injection, powder, for solution, Injection, powder, for solution - Intravenous, Swab - Topical, Swab, For suspension, For suspension - Oral, Tablet, coated, Tablet, coated - Oral
Granuloma Inguinale
, 333.0 mg, 20.0 mg/mL, 0.02 mg/mg, 250.0 mg, 0.03 mg/mg, 0.005 mg/mg, 500.0 mg, 400.0 mg, 200.0 mg/mL, 400.0 mg/mL, 0.008 mL/mL, 0.0005 mg/mg, 20.0 mg, 600.0 mg, 1000.0 mg, 0.5 %, 4.0 %, 200.0 mg, 2.0 %, 50.0 mg/mL, 5.0 mg/mL, 15.0 mg/mL, 3.1 mg/mg, 100.0 mg/mL, 3.0 %, 125.0 mg/mL, 25.0 mg/mL, 250.0 mg/mL, 40.0 mg/mL, 0.0012 mg/mg, 0.12 mg/mg
, Kit, Solution, Topical, Solution - Topical, Gel, Gel - Topical, Oral, Tablet, film coated, Tablet, film coated - Oral, Capsule, delayed release, Capsule, delayed release - Oral, Tablet, delayed release, Tablet, delayed release - Oral, Ointment, Ophthalmic, Ointment - Ophthalmic, Granule, for suspension - Oral, Tablet, Tablet - Oral, Suspension, Suspension - Oral, Granule, for suspension, Capsule, delayed release pellets, Capsule, delayed release pellets - Oral, Intravenous, Powder, for solution, Powder, for solution - Intravenous, Liquid, Liquid - Oral, Powder, for solution - Oral, Capsule, Capsule - Oral, Powder, Powder - Oral, Lotion, Lotion - Topical, Lotion; Swab, Lotion; Swab - Topical, Kit - Topical, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous, Powder, for suspension, Powder, for suspension - Oral, Capsule, Delayed Release - Oral, Capsule, Delayed Release, Ointment - Topical, Wafer, Wafer - Oral, Capsule, coated pellets, Capsule, coated pellets - Oral, Injection, powder, for solution, Injection, powder, for solution - Intravenous, Swab - Topical, Swab, For suspension, For suspension - Oral, Tablet, coated, Tablet, coated - Oral
Whooping Cough
, 333.0 mg, 20.0 mg/mL, 0.02 mg/mg, 250.0 mg, 0.03 mg/mg, 0.005 mg/mg, 500.0 mg, 400.0 mg, 200.0 mg/mL, 400.0 mg/mL, 0.008 mL/mL, 0.0005 mg/mg, 20.0 mg, 600.0 mg, 1000.0 mg, 0.5 %, 4.0 %, 200.0 mg, 2.0 %, 50.0 mg/mL, 5.0 mg/mL, 15.0 mg/mL, 3.1 mg/mg, 100.0 mg/mL, 3.0 %, 125.0 mg/mL, 25.0 mg/mL, 250.0 mg/mL, 40.0 mg/mL, 0.0012 mg/mg, 0.12 mg/mg
, Kit, Solution, Topical, Solution - Topical, Gel, Gel - Topical, Oral, Tablet, film coated, Tablet, film coated - Oral, Capsule, delayed release, Capsule, delayed release - Oral, Tablet, delayed release, Tablet, delayed release - Oral, Ointment, Ophthalmic, Ointment - Ophthalmic, Granule, for suspension - Oral, Tablet, Tablet - Oral, Suspension, Suspension - Oral, Granule, for suspension, Capsule, delayed release pellets, Capsule, delayed release pellets - Oral, Intravenous, Powder, for solution, Powder, for solution - Intravenous, Liquid, Liquid - Oral, Powder, for solution - Oral, Capsule, Capsule - Oral, Powder, Powder - Oral, Lotion, Lotion - Topical, Lotion; Swab, Lotion; Swab - Topical, Kit - Topical, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous, Powder, for suspension, Powder, for suspension - Oral, Capsule, Delayed Release - Oral, Capsule, Delayed Release, Ointment - Topical, Wafer, Wafer - Oral, Capsule, coated pellets, Capsule, coated pellets - Oral, Injection, powder, for solution, Injection, powder, for solution - Intravenous, Swab - Topical, Swab, For suspension, For suspension - Oral, Tablet, coated, Tablet, coated - Oral
Bacterial Infections
, 333.0 mg, 20.0 mg/mL, 0.02 mg/mg, 250.0 mg, 0.03 mg/mg, 0.005 mg/mg, 500.0 mg, 400.0 mg, 200.0 mg/mL, 400.0 mg/mL, 0.008 mL/mL, 0.0005 mg/mg, 20.0 mg, 600.0 mg, 1000.0 mg, 0.5 %, 4.0 %, 200.0 mg, 2.0 %, 50.0 mg/mL, 5.0 mg/mL, 15.0 mg/mL, 3.1 mg/mg, 100.0 mg/mL, 3.0 %, 125.0 mg/mL, 25.0 mg/mL, 250.0 mg/mL, 40.0 mg/mL, 0.0012 mg/mg, 0.12 mg/mg
, Kit, Solution, Topical, Solution - Topical, Gel, Gel - Topical, Oral, Tablet, film coated, Tablet, film coated - Oral, Capsule, delayed release, Capsule, delayed release - Oral, Tablet, delayed release, Tablet, delayed release - Oral, Ointment, Ophthalmic, Ointment - Ophthalmic, Granule, for suspension - Oral, Tablet, Tablet - Oral, Suspension, Suspension - Oral, Granule, for suspension, Capsule, delayed release pellets, Capsule, delayed release pellets - Oral, Intravenous, Powder, for solution, Powder, for solution - Intravenous, Liquid, Liquid - Oral, Powder, for solution - Oral, Capsule, Capsule - Oral, Powder, Powder - Oral, Lotion, Lotion - Topical, Lotion; Swab, Lotion; Swab - Topical, Kit - Topical, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous, Powder, for suspension, Powder, for suspension - Oral, Capsule, Delayed Release - Oral, Capsule, Delayed Release, Ointment - Topical, Wafer, Wafer - Oral, Capsule, coated pellets, Capsule, coated pellets - Oral, Injection, powder, for solution, Injection, powder, for solution - Intravenous, Swab - Topical, Swab, For suspension, For suspension - Oral, Tablet, coated, Tablet, coated - Oral
Urethritis
, 333.0 mg, 20.0 mg/mL, 0.02 mg/mg, 250.0 mg, 0.03 mg/mg, 0.005 mg/mg, 500.0 mg, 400.0 mg, 200.0 mg/mL, 400.0 mg/mL, 0.008 mL/mL, 0.0005 mg/mg, 20.0 mg, 600.0 mg, 1000.0 mg, 0.5 %, 4.0 %, 200.0 mg, 2.0 %, 50.0 mg/mL, 5.0 mg/mL, 15.0 mg/mL, 3.1 mg/mg, 100.0 mg/mL, 3.0 %, 125.0 mg/mL, 25.0 mg/mL, 250.0 mg/mL, 40.0 mg/mL, 0.0012 mg/mg, 0.12 mg/mg
, Kit, Solution, Topical, Solution - Topical, Gel, Gel - Topical, Oral, Tablet, film coated, Tablet, film coated - Oral, Capsule, delayed release, Capsule, delayed release - Oral, Tablet, delayed release, Tablet, delayed release - Oral, Ointment, Ophthalmic, Ointment - Ophthalmic, Granule, for suspension - Oral, Tablet, Tablet - Oral, Suspension, Suspension - Oral, Granule, for suspension, Capsule, delayed release pellets, Capsule, delayed release pellets - Oral, Intravenous, Powder, for solution, Powder, for solution - Intravenous, Liquid, Liquid - Oral, Powder, for solution - Oral, Capsule, Capsule - Oral, Powder, Powder - Oral, Lotion, Lotion - Topical, Lotion; Swab, Lotion; Swab - Topical, Kit - Topical, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous, Powder, for suspension, Powder, for suspension - Oral, Capsule, Delayed Release - Oral, Capsule, Delayed Release, Ointment - Topical, Wafer, Wafer - Oral, Capsule, coated pellets, Capsule, coated pellets - Oral, Injection, powder, for solution, Injection, powder, for solution - Intravenous, Swab - Topical, Swab, For suspension, For suspension - Oral, Tablet, coated, Tablet, coated - Oral
Ophthalmia neonatorum (gonococcal)
, 333.0 mg, 20.0 mg/mL, 0.02 mg/mg, 250.0 mg, 0.03 mg/mg, 0.005 mg/mg, 500.0 mg, 400.0 mg, 200.0 mg/mL, 400.0 mg/mL, 0.008 mL/mL, 0.0005 mg/mg, 20.0 mg, 600.0 mg, 1000.0 mg, 0.5 %, 4.0 %, 200.0 mg, 2.0 %, 50.0 mg/mL, 5.0 mg/mL, 15.0 mg/mL, 3.1 mg/mg, 100.0 mg/mL, 3.0 %, 125.0 mg/mL, 25.0 mg/mL, 250.0 mg/mL, 40.0 mg/mL, 0.0012 mg/mg, 0.12 mg/mg
, Kit, Solution, Topical, Solution - Topical, Gel, Gel - Topical, Oral, Tablet, film coated, Tablet, film coated - Oral, Capsule, delayed release, Capsule, delayed release - Oral, Tablet, delayed release, Tablet, delayed release - Oral, Ointment, Ophthalmic, Ointment - Ophthalmic, Granule, for suspension - Oral, Tablet, Tablet - Oral, Suspension, Suspension - Oral, Granule, for suspension, Capsule, delayed release pellets, Capsule, delayed release pellets - Oral, Intravenous, Powder, for solution, Powder, for solution - Intravenous, Liquid, Liquid - Oral, Powder, for solution - Oral, Capsule, Capsule - Oral, Powder, Powder - Oral, Lotion, Lotion - Topical, Lotion; Swab, Lotion; Swab - Topical, Kit - Topical, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous, Powder, for suspension, Powder, for suspension - Oral, Capsule, Delayed Release - Oral, Capsule, Delayed Release, Ointment - Topical, Wafer, Wafer - Oral, Capsule, coated pellets, Capsule, coated pellets - Oral, Injection, powder, for solution, Injection, powder, for solution - Intravenous, Swab - Topical, Swab, For suspension, For suspension - Oral, Tablet, coated, Tablet, coated - Oral
Acne Vulgaris
, 333.0 mg, 20.0 mg/mL, 0.02 mg/mg, 250.0 mg, 0.03 mg/mg, 0.005 mg/mg, 500.0 mg, 400.0 mg, 200.0 mg/mL, 400.0 mg/mL, 0.008 mL/mL, 0.0005 mg/mg, 20.0 mg, 600.0 mg, 1000.0 mg, 0.5 %, 4.0 %, 200.0 mg, 2.0 %, 50.0 mg/mL, 5.0 mg/mL, 15.0 mg/mL, 3.1 mg/mg, 100.0 mg/mL, 3.0 %, 125.0 mg/mL, 25.0 mg/mL, 250.0 mg/mL, 40.0 mg/mL, 0.0012 mg/mg, 0.12 mg/mg
, Kit, Solution, Topical, Solution - Topical, Gel, Gel - Topical, Oral, Tablet, film coated, Tablet, film coated - Oral, Capsule, delayed release, Capsule, delayed release - Oral, Tablet, delayed release, Tablet, delayed release - Oral, Ointment, Ophthalmic, Ointment - Ophthalmic, Granule, for suspension - Oral, Tablet, Tablet - Oral, Suspension, Suspension - Oral, Granule, for suspension, Capsule, delayed release pellets, Capsule, delayed release pellets - Oral, Intravenous, Powder, for solution, Powder, for solution - Intravenous, Liquid, Liquid - Oral, Powder, for solution - Oral, Capsule, Capsule - Oral, Powder, Powder - Oral, Lotion, Lotion - Topical, Lotion; Swab, Lotion; Swab - Topical, Kit - Topical, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous, Powder, for suspension, Powder, for suspension - Oral, Capsule, Delayed Release - Oral, Capsule, Delayed Release, Ointment - Topical, Wafer, Wafer - Oral, Capsule, coated pellets, Capsule, coated pellets - Oral, Injection, powder, for solution, Injection, powder, for solution - Intravenous, Swab - Topical, Swab, For suspension, For suspension - Oral, Tablet, coated, Tablet, coated - Oral
Listeriosis
, 333.0 mg, 20.0 mg/mL, 0.02 mg/mg, 250.0 mg, 0.03 mg/mg, 0.005 mg/mg, 500.0 mg, 400.0 mg, 200.0 mg/mL, 400.0 mg/mL, 0.008 mL/mL, 0.0005 mg/mg, 20.0 mg, 600.0 mg, 1000.0 mg, 0.5 %, 4.0 %, 200.0 mg, 2.0 %, 50.0 mg/mL, 5.0 mg/mL, 15.0 mg/mL, 3.1 mg/mg, 100.0 mg/mL, 3.0 %, 125.0 mg/mL, 25.0 mg/mL, 250.0 mg/mL, 40.0 mg/mL, 0.0012 mg/mg, 0.12 mg/mg
, Kit, Solution, Topical, Solution - Topical, Gel, Gel - Topical, Oral, Tablet, film coated, Tablet, film coated - Oral, Capsule, delayed release, Capsule, delayed release - Oral, Tablet, delayed release, Tablet, delayed release - Oral, Ointment, Ophthalmic, Ointment - Ophthalmic, Granule, for suspension - Oral, Tablet, Tablet - Oral, Suspension, Suspension - Oral, Granule, for suspension, Capsule, delayed release pellets, Capsule, delayed release pellets - Oral, Intravenous, Powder, for solution, Powder, for solution - Intravenous, Liquid, Liquid - Oral, Powder, for solution - Oral, Capsule, Capsule - Oral, Powder, Powder - Oral, Lotion, Lotion - Topical, Lotion; Swab, Lotion; Swab - Topical, Kit - Topical, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous, Powder, for suspension, Powder, for suspension - Oral, Capsule, Delayed Release - Oral, Capsule, Delayed Release, Ointment - Topical, Wafer, Wafer - Oral, Capsule, coated pellets, Capsule, coated pellets - Oral, Injection, powder, for solution, Injection, powder, for solution - Intravenous, Swab - Topical, Swab, For suspension, For suspension - Oral, Tablet, coated, Tablet, coated - Oral
Acne Vulgaris
, 333.0 mg, 20.0 mg/mL, 0.02 mg/mg, 250.0 mg, 0.03 mg/mg, 0.005 mg/mg, 500.0 mg, 400.0 mg, 200.0 mg/mL, 400.0 mg/mL, 0.008 mL/mL, 0.0005 mg/mg, 20.0 mg, 600.0 mg, 1000.0 mg, 0.5 %, 4.0 %, 200.0 mg, 2.0 %, 50.0 mg/mL, 5.0 mg/mL, 15.0 mg/mL, 3.1 mg/mg, 100.0 mg/mL, 3.0 %, 125.0 mg/mL, 25.0 mg/mL, 250.0 mg/mL, 40.0 mg/mL, 0.0012 mg/mg, 0.12 mg/mg
, Kit, Solution, Topical, Solution - Topical, Gel, Gel - Topical, Oral, Tablet, film coated, Tablet, film coated - Oral, Capsule, delayed release, Capsule, delayed release - Oral, Tablet, delayed release, Tablet, delayed release - Oral, Ointment, Ophthalmic, Ointment - Ophthalmic, Granule, for suspension - Oral, Tablet, Tablet - Oral, Suspension, Suspension - Oral, Granule, for suspension, Capsule, delayed release pellets, Capsule, delayed release pellets - Oral, Intravenous, Powder, for solution, Powder, for solution - Intravenous, Liquid, Liquid - Oral, Powder, for solution - Oral, Capsule, Capsule - Oral, Powder, Powder - Oral, Lotion, Lotion - Topical, Lotion; Swab, Lotion; Swab - Topical, Kit - Topical, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous, Powder, for suspension, Powder, for suspension - Oral, Capsule, Delayed Release - Oral, Capsule, Delayed Release, Ointment - Topical, Wafer, Wafer - Oral, Capsule, coated pellets, Capsule, coated pellets - Oral, Injection, powder, for solution, Injection, powder, for solution - Intravenous, Swab - Topical, Swab, For suspension, For suspension - Oral, Tablet, coated, Tablet, coated - Oral
Endophthalmitis
, 333.0 mg, 20.0 mg/mL, 0.02 mg/mg, 250.0 mg, 0.03 mg/mg, 0.005 mg/mg, 500.0 mg, 400.0 mg, 200.0 mg/mL, 400.0 mg/mL, 0.008 mL/mL, 0.0005 mg/mg, 20.0 mg, 600.0 mg, 1000.0 mg, 0.5 %, 4.0 %, 200.0 mg, 2.0 %, 50.0 mg/mL, 5.0 mg/mL, 15.0 mg/mL, 3.1 mg/mg, 100.0 mg/mL, 3.0 %, 125.0 mg/mL, 25.0 mg/mL, 250.0 mg/mL, 40.0 mg/mL, 0.0012 mg/mg, 0.12 mg/mg
, Kit, Solution, Topical, Solution - Topical, Gel, Gel - Topical, Oral, Tablet, film coated, Tablet, film coated - Oral, Capsule, delayed release, Capsule, delayed release - Oral, Tablet, delayed release, Tablet, delayed release - Oral, Ointment, Ophthalmic, Ointment - Ophthalmic, Granule, for suspension - Oral, Tablet, Tablet - Oral, Suspension, Suspension - Oral, Granule, for suspension, Capsule, delayed release pellets, Capsule, delayed release pellets - Oral, Intravenous, Powder, for solution, Powder, for solution - Intravenous, Liquid, Liquid - Oral, Powder, for solution - Oral, Capsule, Capsule - Oral, Powder, Powder - Oral, Lotion, Lotion - Topical, Lotion; Swab, Lotion; Swab - Topical, Kit - Topical, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous, Powder, for suspension, Powder, for suspension - Oral, Capsule, Delayed Release - Oral, Capsule, Delayed Release, Ointment - Topical, Wafer, Wafer - Oral, Capsule, coated pellets, Capsule, coated pellets - Oral, Injection, powder, for solution, Injection, powder, for solution - Intravenous, Swab - Topical, Swab, For suspension, For suspension - Oral, Tablet, coated, Tablet, coated - Oral
Conjunctivitis
, 333.0 mg, 20.0 mg/mL, 0.02 mg/mg, 250.0 mg, 0.03 mg/mg, 0.005 mg/mg, 500.0 mg, 400.0 mg, 200.0 mg/mL, 400.0 mg/mL, 0.008 mL/mL, 0.0005 mg/mg, 20.0 mg, 600.0 mg, 1000.0 mg, 0.5 %, 4.0 %, 200.0 mg, 2.0 %, 50.0 mg/mL, 5.0 mg/mL, 15.0 mg/mL, 3.1 mg/mg, 100.0 mg/mL, 3.0 %, 125.0 mg/mL, 25.0 mg/mL, 250.0 mg/mL, 40.0 mg/mL, 0.0012 mg/mg, 0.12 mg/mg
, Kit, Solution, Topical, Solution - Topical, Gel, Gel - Topical, Oral, Tablet, film coated, Tablet, film coated - Oral, Capsule, delayed release, Capsule, delayed release - Oral, Tablet, delayed release, Tablet, delayed release - Oral, Ointment, Ophthalmic, Ointment - Ophthalmic, Granule, for suspension - Oral, Tablet, Tablet - Oral, Suspension, Suspension - Oral, Granule, for suspension, Capsule, delayed release pellets, Capsule, delayed release pellets - Oral, Intravenous, Powder, for solution, Powder, for solution - Intravenous, Liquid, Liquid - Oral, Powder, for solution - Oral, Capsule, Capsule - Oral, Powder, Powder - Oral, Lotion, Lotion - Topical, Lotion; Swab, Lotion; Swab - Topical, Kit - Topical, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous, Powder, for suspension, Powder, for suspension - Oral, Capsule, Delayed Release - Oral, Capsule, Delayed Release, Ointment - Topical, Wafer, Wafer - Oral, Capsule, coated pellets, Capsule, coated pellets - Oral, Injection, powder, for solution, Injection, powder, for solution - Intravenous, Swab - Topical, Swab, For suspension, For suspension - Oral, Tablet, coated, Tablet, coated - Oral
Rheumatic Fever
, 333.0 mg, 20.0 mg/mL, 0.02 mg/mg, 250.0 mg, 0.03 mg/mg, 0.005 mg/mg, 500.0 mg, 400.0 mg, 200.0 mg/mL, 400.0 mg/mL, 0.008 mL/mL, 0.0005 mg/mg, 20.0 mg, 600.0 mg, 1000.0 mg, 0.5 %, 4.0 %, 200.0 mg, 2.0 %, 50.0 mg/mL, 5.0 mg/mL, 15.0 mg/mL, 3.1 mg/mg, 100.0 mg/mL, 3.0 %, 125.0 mg/mL, 25.0 mg/mL, 250.0 mg/mL, 40.0 mg/mL, 0.0012 mg/mg, 0.12 mg/mg
, Kit, Solution, Topical, Solution - Topical, Gel, Gel - Topical, Oral, Tablet, film coated, Tablet, film coated - Oral, Capsule, delayed release, Capsule, delayed release - Oral, Tablet, delayed release, Tablet, delayed release - Oral, Ointment, Ophthalmic, Ointment - Ophthalmic, Granule, for suspension - Oral, Tablet, Tablet - Oral, Suspension, Suspension - Oral, Granule, for suspension, Capsule, delayed release pellets, Capsule, delayed release pellets - Oral, Intravenous, Powder, for solution, Powder, for solution - Intravenous, Liquid, Liquid - Oral, Powder, for solution - Oral, Capsule, Capsule - Oral, Powder, Powder - Oral, Lotion, Lotion - Topical, Lotion; Swab, Lotion; Swab - Topical, Kit - Topical, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous, Powder, for suspension, Powder, for suspension - Oral, Capsule, Delayed Release - Oral, Capsule, Delayed Release, Ointment - Topical, Wafer, Wafer - Oral, Capsule, coated pellets, Capsule, coated pellets - Oral, Injection, powder, for solution, Injection, powder, for solution - Intravenous, Swab - Topical, Swab, For suspension, For suspension - Oral, Tablet, coated, Tablet, coated - Oral
Respiratory Tract Infections
, 333.0 mg, 20.0 mg/mL, 0.02 mg/mg, 250.0 mg, 0.03 mg/mg, 0.005 mg/mg, 500.0 mg, 400.0 mg, 200.0 mg/mL, 400.0 mg/mL, 0.008 mL/mL, 0.0005 mg/mg, 20.0 mg, 600.0 mg, 1000.0 mg, 0.5 %, 4.0 %, 200.0 mg, 2.0 %, 50.0 mg/mL, 5.0 mg/mL, 15.0 mg/mL, 3.1 mg/mg, 100.0 mg/mL, 3.0 %, 125.0 mg/mL, 25.0 mg/mL, 250.0 mg/mL, 40.0 mg/mL, 0.0012 mg/mg, 0.12 mg/mg
, Kit, Solution, Topical, Solution - Topical, Gel, Gel - Topical, Oral, Tablet, film coated, Tablet, film coated - Oral, Capsule, delayed release, Capsule, delayed release - Oral, Tablet, delayed release, Tablet, delayed release - Oral, Ointment, Ophthalmic, Ointment - Ophthalmic, Granule, for suspension - Oral, Tablet, Tablet - Oral, Suspension, Suspension - Oral, Granule, for suspension, Capsule, delayed release pellets, Capsule, delayed release pellets - Oral, Intravenous, Powder, for solution, Powder, for solution - Intravenous, Liquid, Liquid - Oral, Powder, for solution - Oral, Capsule, Capsule - Oral, Powder, Powder - Oral, Lotion, Lotion - Topical, Lotion; Swab, Lotion; Swab - Topical, Kit - Topical, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous, Powder, for suspension, Powder, for suspension - Oral, Capsule, Delayed Release - Oral, Capsule, Delayed Release, Ointment - Topical, Wafer, Wafer - Oral, Capsule, coated pellets, Capsule, coated pellets - Oral, Injection, powder, for solution, Injection, powder, for solution - Intravenous, Swab - Topical, Swab, For suspension, For suspension - Oral, Tablet, coated, Tablet, coated - Oral

Warnings

E-Mycin Contraindications
Condition
Risk Level
Notes
Pulse Frequency
Do Not Combine
Pulse Frequency
Do Not Combine
Pulse Frequency
Do Not Combine
Pulse Frequency
Do Not Combine
Pulse Frequency
Do Not Combine
Pulse Frequency
Do Not Combine
Pulse Frequency
Do Not Combine
Pulse Frequency
Do Not Combine
Severe Hypersensitivity Reactions
Do Not Combine
Erythromycin may interact with Pulse Frequency
There are 20 known major drug interactions with E-Mycin.
Common E-Mycin Drug Interactions
Drug Name
Risk Level
Description
Abemaciclib
Major
The serum concentration of Abemaciclib can be increased when it is combined with Erythromycin.
Acalabrutinib
Major
The metabolism of Acalabrutinib can be decreased when combined with Erythromycin.
Alectinib
Major
The metabolism of Alectinib can be decreased when combined with Erythromycin.
Alpelisib
Major
The metabolism of Alpelisib can be decreased when combined with Erythromycin.
Aminophylline
Major
The metabolism of Aminophylline can be decreased when combined with Erythromycin.
E-Mycin Toxicity & Overdose RiskThe toxic dose of erythromycin in rats is 9272mg/kg. Overdosing on erythromycin may cause diarrhea, nausea, stomach cramps, and vomiting. If an overdose is suspected, discontinue the drug immediately and seek medical help. Erythromycin cannot be removed from the body using dialysis.

E-Mycin Novel Uses: Which Conditions Have a Clinical Trial Featuring E-Mycin?

Currently, 53 active clinical trials are being conducted to explore the use of E-Mycin to address Streptococcus pyogenes, Treponema pallidum infection and Rheumatic Fever.
Condition
Clinical Trials
Trial Phases
Common Cold
3 Actively Recruiting
Not Applicable
Listeriosis
0 Actively Recruiting
urogenital infections during pregnancy
0 Actively Recruiting
Respiratory Tract Infections
0 Actively Recruiting
Primary Syphilis
0 Actively Recruiting
Communicable Diseases
0 Actively Recruiting
Acne Vulgaris
0 Actively Recruiting
Urethritis
0 Actively Recruiting
Chlamydia Trachomatis
0 Actively Recruiting
Acne Vulgaris
0 Actively Recruiting
Communicable Diseases
0 Actively Recruiting
Legionella pneumophila
0 Actively Recruiting
treponema pallidum infection
0 Actively Recruiting
Corynebacterium minutissimum infection
0 Actively Recruiting
Listeria monocytogenes infection
0 Actively Recruiting
Acne Vulgaris
0 Actively Recruiting
Ureaplasma urealyticum
0 Actively Recruiting
Acute Otitis Media caused by Haemophilus Influenzae
0 Actively Recruiting
Pneumococcal Infections
0 Actively Recruiting
patients with intolerance or contraindications to tetracycline use
0 Actively Recruiting

E-Mycin Reviews: What are patients saying about E-Mycin?

5Patient Review
7/24/2015
E-Mycin for Middle Ear Infection
This antibiotic was terrible. The abdominal pain it caused was much worse than the flu it was prescribed for. If offered, tell them to try again...
4.7Patient Review
4/27/2011
E-Mycin for Bacterial Stomach or Intestine Infection caused by Anthrax
Unfortunately, this medication caused me a lot of pain in my stomach. Even when I took it with meals, I experienced cramping and nausea. I had to call my doctor to ask for something different.
4.7Patient Review
7/12/2012
E-Mycin for Skin Infection
I had some pretty intense cold sweats, nausea and hallucinations.
4.7Patient Review
5/30/2016
E-Mycin for Skin Infection
I saw results from this treatment within a day, though my appetite decreased while I was taking it.
4Patient Review
7/28/2015
E-Mycin for Whooping Cough
I experienced zero negative side effects from this treatment!
2Patient Review
7/13/2015
E-Mycin for Acute Bacterial Infection of the Sinuses
I experienced some serious side effects from this treatment, including cold sweats, dizziness, nausea, and difficulty breathing. My chest felt heavy the entire time.
2Patient Review
7/7/2009
E-Mycin for Severe Sinusitis caused by Streptococcus Pneumoniae
1Patient Review
8/15/2022
E-Mycin for Skin Infection
After taking just one pill (with food, as directed), I had such severe stomach cramps, vomiting, and diarrhea. Never again will I choose this treatment over the skin infection it's meant to address.
1Patient Review
4/9/2013
E-Mycin for Infection of the Middle Ear by S. Pneumoniae Bacteria
Though this drug has helped me to get rid of infections in the past, they always come back a few months later. I also don't seem to experience any side effects, which is great.
image of drug pills surrounding a glass of water symbolizing drug consumption

Patient Q&A Section about e-mycin

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Is e-Mycin a penicillin?

"E-Mycin is an antibiotic that is effective against patients with a history of rheumatic disease who are allergic to penicillin antibiotics."

Answered by AI

What does e-Mycin stand for?

"Erythromycin is a type of antibiotic that is used to treat infections caused by bacteria. Erythromycin belongs to a class of drugs called macrolide antibiotics, which work by either killing the bacteria that cause an infection or by stopping the growth of the bacteria."

Answered by AI

Which side effect is common of e-Mycin?

"The serious side effect of this drug is a skin rash. However, other side effects may include severe stomach pain, yellowing of the skin or whites of the eyes, or pale feces with dark urine. These could be signs of problems with the pancreas, liver, or gallbladder."

Answered by AI

What is e-Mycin used to treat?

"It is used to treat certain bacterial infections, to control acne in addition to other acne treatments, and to prevent infections in people with a history of rheumatic disease, congenital heart disease or other acquired valvular heart disease and who are allergic to penicillin antibiotics."

Answered by AI

Clinical Trials for E-Mycin

Image of Children's Healthcare of Atlanta in Atlanta, United States.

Antibiotic Strategies for Pneumonia in Children

12 - 71
All Sexes
Atlanta, GA
The goal of this clinical trial is to determine if a "watch and wait" antibiotic strategy, called Safety Net Antibiotic Prescribing (SNAP), can safely reduce unnecessary antibiotic use while ensuring that children diagnosed with community-acquired pneumonia get better from their illness. The main aims of this study are: * To compare the effectiveness of SNAP versus immediate antibiotic prescribing in children with mild community-acquired pneumonia (CAP) * To identify which patient groups benefit most from the SNAP strategy * To identify factors that shape implementation of each prescribing strategy. Researchers will compare the SNAP strategy (where parents or guardians are instructed to give antibiotics only if their child is not improving after 72 hours, or sooner if they are worsening) to the immediate antibiotic prescribing strategy (where parents or guardians are instructed to give the antibiotics right after their healthcare visit) to see if one strategy is more effective than the other. Participants will be randomly assigned to either the immediate antibiotic group or the SNAP group at enrollment. Participation lasts 14 days with follow-up surveys at 4, 7, and 14 days after enrollment.
Recruiting
Has No Placebo
Children's Healthcare of Atlanta (+3 Sites)Todd Florin, MD, MSCE
Have you considered E-Mycin clinical trials? We made a collection of clinical trials featuring E-Mycin, we think they might fit your search criteria.Go to Trials
Image of Children's Community Pediatrics Brentwood in Pittsburgh, United States.

AI Diagnostic Support for Ear Infections

6 - 24
All Sexes
Pittsburgh, PA
Ear infections are common in young children with cold symptoms, but they can be difficult to diagnose due to small ear canals, child movement, and limited viewing time. In this study, investigators will take photos of the eardrums of children 6-24 months of age with upper respiratory symptoms. The photos will be reviewed by imaging software enhanced with artificial intelligence (AI app) to determine whether the AI app changes how ear infections are diagnosed and treated. The AI app has undergone rigorous study and was found to be highly accurate; but how using this technology affects the diagnosis and treatment by clinicians has not been studied. This research may help improve diagnostic accuracy for ear infections and ensure antibiotics are prescribed only for those children who have definite ear infections.
Waitlist Available
Has No Placebo
Children's Community Pediatrics Brentwood (+1 Sites)Timothy R Shope, MD, MPHMerck Sharp & Dohme LLC
Image of Maternity Centre of Hamilton in Hamilton, Canada.

Rapid Test for Syphilis

13 - 49
All Sexes
Hamilton, Canada
The goal of this clinical trial is to learn if a finger-prick blood test for rapid diagnosis of syphilis infection can be implemented in a low-barrier prenatal clinic for people at risk of syphilis in pregnancy. The test gives results in 5 minutes and also tests for HIV. The main questions the study aims to answer are: * How often do pregnant people at risk of syphilis agree to the rapid test? * How well do healthcare providers perform the rapid test? * Does the rapid test speed up diagnosis and treatment of syphilis in pregnant people and their sexual partners? Participants will: * Give feedback about why they did or did not want to take the rapid test, and what their experience was taking the test; and * Share information about their health, pregnancy, and syphilis treatment (if applicable).
Recruiting
Has No Placebo
Maternity Centre of HamiltonLaura K Erdman, MD PhD FRCPC
Image of Benioff Children's Hospital - Oakland in Oakland, United States.

Decision Support for Lower Respiratory Infections in Children

6 - 17
All Sexes
Oakland, CA
Eliminating inappropriate antibiotic use in pediatric lower respiratory tract infections (LRTI) is the central focus of this research. LRTIs (pneumonia, bronchiolitis, and infection-related exacerbations of asthma) account for nearly one-third of all emergency department (ED) visits and 40% of all infection-related hospitalizations in US children. LRTIs also account for more antibiotic use in children's hospitals than any other condition, despite most LRTIs being viral in nature. Inappropriate antibiotics are associated with substantial adverse effects. Accordingly, national guidelines strongly discourage routine antibiotic use for bronchiolitis and acute asthma and argue for significantly reducing antibiotic exposure (initiation, spectrum, and duration) in pneumonia. To address the problem of inappropriate antibiotic use, hospital-based antimicrobial stewardship programs (ASPs) are now common nationwide, and these programs have demonstrated effectiveness in some hospital settings. Unfortunately, traditional ASP approaches do not translate well to the fast-paced and unpredictable ED environment, and hospital-based ASP resources are finite and not always immediately available. Clinical decision support (CDS) embedded within the electronic health record (EHR) is a strategy that could address the ED antibiotic stewardship gap. Informed by a deep understanding of the key facilitators and barriers to using CDS to support appropriate antibiotic use in ED and hospital settings, the investigators have developed two stewardship-focused CDS interventions for pediatric LRTI. The overarching goal of this research is to rigorously evaluate the implementation and effectiveness of these CDS tools, alone and in combination, against usual care only in a pragmatic randomized clinical trial at 3 U.S. children's hospitals.
Recruiting
Has No Placebo
Benioff Children's Hospital - Oakland (+2 Sites)Derek J Williams, MD, MPH
Have you considered E-Mycin clinical trials? We made a collection of clinical trials featuring E-Mycin, we think they might fit your search criteria.Go to Trials
Image of University of Pennsylvania Primary Care Practice in Philadelphia, United States.

Rapid Testing for Upper Respiratory Tract Infection

18+
All Sexes
Philadelphia, PA
The goal of this study is to understand the use of point of care (POC) testing devices in primary care offices to help clinicians diagnose and appropriately treat patients who have symptoms of upper respiratory infections (URIs). The study will use the BIOFIRE® SPOTFIRE® Respiratory (R) Panel testing device, which is FDA-cleared and CLIA-Waived. This panel can identify up to 15 different viruses and bacteria that can cause URIs. These POC devices will be installed in primary care clinics within the University of Pennsylvania Health System. Patients who come to the clinic with cold-like symptoms (runny nose, cough) will be offered the test. If the patient agrees to the test, their clinician will use a swab to take a small sample of fluid from their nose. This swab will then be tested within the POC device and results will be available within 15 minutes. The results of this sample will be shared with the patient, and their clinician can use the results to help decide the most appropriate medical treatment for the patient. Patients who agree to take the test will be asked to answer a short survey about the test and their experience. Clinicians will also be surveyed to share their thoughts with using the test in their clinics. Focus groups of practice staff and clinicians will also be conducted to understand any potential challenges for using this test in practice. Results from the tests and the surveys will help researchers understand the value of the test to support antibiotic stewardship efforts in primary care clinic settings.
Waitlist Available
Has No Placebo
University of Pennsylvania Primary Care Practice
Have you considered E-Mycin clinical trials? We made a collection of clinical trials featuring E-Mycin, we think they might fit your search criteria.Go to Trials
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Terms of Service·Privacy Policy·Cookies·Security